

TETRAPHASE PHARMACEUTICALS INC

Form 8-K

December 19, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 19, 2016

Tetraphase Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction

of incorporation)

001-35837
(Commission

File Number)

20-5276217
(IRS Employer

Identification No.)

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 8-K

480 Arsenal Street, Suite 110,

Watertown, Massachusetts

(Address of principal executive offices)

Registrant's telephone number, including area code: (617) 715-3600

02472

(Zip Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On December 19, 2016, Tetrphase Pharmaceuticals, Inc. (the Company), issued a press release announcing that, during the second half of 2017, it plans to file a Marketing Authorization Application to the European Medicines Agency for the intravenous (IV) form of its antibiotic candidate eravacycline for the treatment of complicated intra-abdominal infections. The Company also announced that, during the first quarter of 2017, it plans to initiate IGNITE3, a randomized, multi-center, double-blind, phase 3 clinical trial evaluating the efficacy and safety of once-daily IV eravacycline compared to ertapenem for the treatment of complicated urinary tract infections.

A copy of the press release announcing these events has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 19, 2016

By: /s/ Maria D. Stahl
Maria D. Stahl
Senior Vice President, General Counsel

EXHIBIT INDEX

Exhibit

No.	Description
99.1	Press Release issued by Tetrphase Pharmaceuticals, Inc., dated December 19, 2016.